Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexarotene and Capecitabine in Metastatic TNBC
NCT04664829Phase 1Completed
- Sponsor
- National Cancer Centre Singapore
- Start
- Oct 2020
- Primary completion
- Aug 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bexarotene in triple-negative breast cancer (TNBC), sponsored by National Cancer Centre Singapore. Primary endpoints: Tumour transcriptome by RNA sequencing at 2 years and Tumour protein profile by multiplex immunohistochemistry at 2 years. Started Oct 2020; status: completed.
02
Drugs
bexarotene
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04664829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04664829.